CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH Biotech Investing
Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial Biotech Investing
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California Biotech Investing
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic Biotech Investing
Bristol-Myers Squibb’s Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Biotech Investing
NanoSphere Health Sciences’ Brand Evolve Formulas Expanding Rapidly Across Colorado and Beyond Biotech Investing
XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa Biotech Investing
